# Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.

> **NCT02315638** · — · TERMINATED · sponsor: **Tacere Therapeutics, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02315638
- **Lead sponsor:** Tacere Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2018-09-24
- **Final completion:** 2018-09-24
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Long term safety follow-up no longer required
- **Last updated:** 2018-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02315638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02315638, "Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02315638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*